Prot #UMCC 2019.116: NU UM21I01: A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer (BilT-04)

Project: Research project

Project Details

StatusActive
Effective start/end date4/21/20 → 10/10/26

Funding

  • University of Michigan (Prot #UMCC 2019.116: NU UM21I01 // Prot #UMCC 2019.116: NU UM...)
  • Rafael Pharmaceuticals, Inc. (Prot #UMCC 2019.116: NU UM21I01 // Prot #UMCC 2019.116: NU UM...)